Join
Live feed
·
PRReleasevia Quantisnow
Artelo Biosciences Inc. logo

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

ByQuantisnow·Wall Street's wire, on your screen.
ARTL· Artelo Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARTL (Artelo Biosciences Inc.) and more on Quantisnow.